NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free IVA Stock Alerts $2.97 -0.19 (-6.01%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.95▼$3.0650-Day Range$2.97▼$3.8952-Week Range$2.95▼$5.05Volume12,842 shsAverage Volume12,043 shsMarket Capitalization$155.87 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Inventiva alerts: Email Address Inventiva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside472.4% Upside$17.00 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.21) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector686th out of 915 stocksPharmaceutical Preparations Industry321st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInventiva has only been the subject of 2 research reports in the past 90 days.Read more about Inventiva's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently increased by 3.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 2.2 News and Social Media Coverage News SentimentInventiva has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inventiva this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($2.21) to ($2.34) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Inventiva Stock (NASDAQ:IVA)Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesJune 11, 2024 | americanbankingnews.comBrokerages Set Inventiva S.A. (NASDAQ:IVA) Target Price at $17.00May 30, 2024 | globenewswire.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 28, 2024 | seekingalpha.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces two scientific presentations at the EASL International Liver Congress 2024May 22, 2024 | globenewswire.comInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024May 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports 2024 First Quarter Financial Information and provides a corporate updateMay 21, 2024 | globenewswire.comInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateMay 16, 2024 | globenewswire.comInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHMay 14, 2024 | finance.yahoo.comFull Video Coverage: Investor Engagement in Private vs. Public Markets Panel From IPO Edge Bootcamp at NasdaqMay 13, 2024 | globenewswire.comInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorApril 26, 2024 | wsj.comInventiva S.A. ADRApril 19, 2024 | msn.comHepion ends Phase 2 study for NASH drug due to cash restraintsApril 3, 2024 | globenewswire.comInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FApril 1, 2024 | msn.comJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical TrialsApril 1, 2024 | finance.yahoo.comInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)March 28, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | globenewswire.comInventiva announces the nomination of Andre Turenne as DirectorMarch 27, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 full-year resultsMarch 27, 2024 | globenewswire.comInventiva reports its 2023 full-year resultsMarch 22, 2024 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsMarch 21, 2024 | markets.businessinsider.comPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH TreatmentMarch 18, 2024 | markets.businessinsider.comPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA ApprovalMarch 18, 2024 | globenewswire.comInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DSee More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees120Year Founded2011Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$25.00 Low Stock Price Target$11.00 Potential Upside/Downside+472.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.95 Sales & Book Value Annual Sales$18.91 million Price / Sales8.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-4.43Miscellaneous Outstanding Shares52,480,000Free Float35,684,000Market Cap$155.87 million OptionableNot Optionable Beta1.00 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Frederic Cren (Age 58)Co-Founder, CEO & Chairman Comp: $519.9kDr. Pierre Broqua Ph.D. (Age 62)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $449.01kMr. Jean Volatier (Age 59)Deputy GM & CFO Ms. Alice Roudot-Ketelers Pharm.D. (Age 53)Chief Operating Officer Mr. Eric Duranson L.L.M. (Age 50)General Counsel Ms. Nathalie Harroy (Age 57)Head of Human Resources Dr. Michael Cooreman (Age 66)Chief Medical Officer Ms. Pascaline Clerc Ph.D. (Age 44)Executive Vice President of Strategy & Corporate Affairs More ExecutivesKey CompetitorsPliant TherapeuticsNASDAQ:PLRXZymeworksNYSE:ZYMEPhibro Animal HealthNASDAQ:PAHCPraxis Precision MedicinesNASDAQ:PRAXAnaptysBioNASDAQ:ANABView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 10,490 shares on 5/20/2024Ownership: 0.020%View All Institutional Transactions IVA Stock Analysis - Frequently Asked Questions Should I buy or sell Inventiva stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks. What is Inventiva's stock price target for 2024? 7 brokers have issued 1-year target prices for Inventiva's shares. Their IVA share price targets range from $11.00 to $25.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 472.4% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts. How have IVA shares performed in 2024? Inventiva's stock was trading at $4.52 on January 1st, 2024. Since then, IVA shares have decreased by 34.3% and is now trading at $2.97. View the best growth stocks for 2024 here. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. Who are Inventiva's major shareholders? Inventiva's stock is owned by a number of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.02%). How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.